There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.